Venrock Healthcare Capital Par Buys 4,137 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par purchased 4,137 shares of the stock in a transaction dated Monday, February 10th. The stock was purchased at an average price of $9.14 per share, with a total value of $37,812.18. Following the completion of the acquisition, the insider now directly owns 5,090,582 shares in the company, valued at approximately $46,527,919.48. The trade was a 0.08 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 7th, Venrock Healthcare Capital Par acquired 73,649 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average cost of $9.29 per share, with a total value of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock. The shares were acquired at an average cost of $9.22 per share, for a total transaction of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par purchased 43,707 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average cost of $8.76 per share, with a total value of $382,873.32.

KalVista Pharmaceuticals Price Performance

Shares of KALV traded up $0.08 during trading hours on Tuesday, reaching $9.27. 239,790 shares of the company’s stock traded hands, compared to its average volume of 293,951. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $16.88. The business’s fifty day simple moving average is $8.75 and its two-hundred day simple moving average is $10.58. The firm has a market capitalization of $458.12 million, a price-to-earnings ratio of -2.55 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.01. On average, equities research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of KalVista Pharmaceuticals by 67.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,328 shares in the last quarter. Intech Investment Management LLC acquired a new stake in KalVista Pharmaceuticals during the third quarter valued at approximately $126,000. SG Americas Securities LLC bought a new stake in KalVista Pharmaceuticals during the third quarter worth approximately $153,000. Quest Partners LLC acquired a new position in KalVista Pharmaceuticals in the third quarter worth approximately $175,000. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after buying an additional 3,314 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on KALV. Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective on the stock. JMP Securities initiated coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target on the stock. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).